O06.4 Efficacy and cost-effectiveness of qHPV vaccine with imiquimod or podophyllotoxin for patients with anogenital warts (HIPvac) | Sexually Transmitted Infections

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Oral Presentations

O06 – STI/HIV TREATMENT EFFICACY AND EFFECTIVENESS

Monday, July 15, 2019 4:15 PM – 5:45 PM

O06.4 Efficacy and cost-effectiveness of qHPV vaccine with imiquimod or podophyllotoxin for patients with anogenital warts (HIPvac)

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Gilson R, Bennett K, Sandmann F, et al

O06.4 Efficacy and cost-effectiveness of qHPV vaccine with imiquimod or podophyllotoxin for patients with anogenital warts (HIPvac)

Sexually Transmitted Infections 2019;95:A50-A51.